Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
Identifieur interne : 001159 ( Pmc/Corpus ); précédent : 001158; suivant : 001160Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
Auteurs : Ka Phillips ; Rl Milne ; Ma Rookus ; D. Goldgar ; M. Friedlander ; Sa Mclachlan ; S. Buys ; Ac Antoniou ; K. Birch ; Mb Terry ; Df Easton ; P. Weideman ; M. Daly ; N. Andrieu ; Em John ; Mj Hooning ; Il Andrulis ; T. Caldes ; H. Olsson ; Jl HopperSource :
- Hereditary Cancer in Clinical Practice [ 1731-2302 ] ; 2012.
Url:
DOI: 10.1186/1897-4287-10-S2-A11
PubMed: NONE
PubMed Central: 3395384
Links to Exploration step
PMC:3395384Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers</title><author><name sortKey="Phillips, Ka" sort="Phillips, Ka" uniqKey="Phillips K" first="Ka" last="Phillips">Ka Phillips</name><affiliation><nlm:aff id="I1">Peter MacCallum Cancer Centre, Melbourne, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I2">University of Melbourne, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Milne, Rl" sort="Milne, Rl" uniqKey="Milne R" first="Rl" last="Milne">Rl Milne</name><affiliation><nlm:aff id="I2">University of Melbourne, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Rookus, Ma" sort="Rookus, Ma" uniqKey="Rookus M" first="Ma" last="Rookus">Ma Rookus</name><affiliation><nlm:aff id="I3">Netherlands Cancer Institute, Amsterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Goldgar, D" sort="Goldgar, D" uniqKey="Goldgar D" first="D" last="Goldgar">D. Goldgar</name><affiliation><nlm:aff id="I4">University of Utah, Salt Lake City, USA</nlm:aff></affiliation></author><author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M" last="Friedlander">M. Friedlander</name><affiliation><nlm:aff id="I5">Prince of Wales Hospital, Randwick, Australia</nlm:aff></affiliation></author><author><name sortKey="Mclachlan, Sa" sort="Mclachlan, Sa" uniqKey="Mclachlan S" first="Sa" last="Mclachlan">Sa Mclachlan</name><affiliation><nlm:aff id="I6">St Vincent’s Hospital, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Buys, S" sort="Buys, S" uniqKey="Buys S" first="S" last="Buys">S. Buys</name><affiliation><nlm:aff id="I7">Huntsman Cancer Institute, Salt Lake City, USA</nlm:aff></affiliation></author><author><name sortKey="Antoniou, Ac" sort="Antoniou, Ac" uniqKey="Antoniou A" first="Ac" last="Antoniou">Ac Antoniou</name><affiliation><nlm:aff id="I8">University of Cambridge, Cambridge, UK</nlm:aff></affiliation></author><author><name sortKey="Birch, K" sort="Birch, K" uniqKey="Birch K" first="K" last="Birch">K. Birch</name><affiliation><nlm:aff id="I1">Peter MacCallum Cancer Centre, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Terry, Mb" sort="Terry, Mb" uniqKey="Terry M" first="Mb" last="Terry">Mb Terry</name><affiliation><nlm:aff id="I9">Columbia University, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Easton, Df" sort="Easton, Df" uniqKey="Easton D" first="Df" last="Easton">Df Easton</name><affiliation><nlm:aff id="I8">University of Cambridge, Cambridge, UK</nlm:aff></affiliation></author><author><name sortKey="Weideman, P" sort="Weideman, P" uniqKey="Weideman P" first="P" last="Weideman">P. Weideman</name><affiliation><nlm:aff id="I1">Peter MacCallum Cancer Centre, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Daly, M" sort="Daly, M" uniqKey="Daly M" first="M" last="Daly">M. Daly</name><affiliation><nlm:aff id="I10">Fox Chase Cancer Center, Philadelphia, USA</nlm:aff></affiliation></author><author><name sortKey="Andrieu, N" sort="Andrieu, N" uniqKey="Andrieu N" first="N" last="Andrieu">N. Andrieu</name><affiliation><nlm:aff id="I11">Institut Curie, Paris, France</nlm:aff></affiliation></author><author><name sortKey="John, Em" sort="John, Em" uniqKey="John E" first="Em" last="John">Em John</name><affiliation><nlm:aff id="I12">Northern California Cancer Center, Fremont, USA</nlm:aff></affiliation></author><author><name sortKey="Hooning, Mj" sort="Hooning, Mj" uniqKey="Hooning M" first="Mj" last="Hooning">Mj Hooning</name><affiliation><nlm:aff id="I13">Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Andrulis, Il" sort="Andrulis, Il" uniqKey="Andrulis I" first="Il" last="Andrulis">Il Andrulis</name><affiliation><nlm:aff id="I14">Ontario Cancer Genetics Network, Cancer Care Ontario, Toronto, Canada</nlm:aff></affiliation></author><author><name sortKey="Caldes, T" sort="Caldes, T" uniqKey="Caldes T" first="T" last="Caldes">T. Caldes</name><affiliation><nlm:aff id="I15">Hospital Clinico San Carlos, Madrid, Spain</nlm:aff></affiliation></author><author><name sortKey="Olsson, H" sort="Olsson, H" uniqKey="Olsson H" first="H" last="Olsson">H. Olsson</name><affiliation><nlm:aff id="I16">Lund University Hospital, Lund, Sweden</nlm:aff></affiliation></author><author><name sortKey="Hopper, Jl" sort="Hopper, Jl" uniqKey="Hopper J" first="Jl" last="Hopper">Jl Hopper</name><affiliation><nlm:aff id="I2">University of Melbourne, Melbourne, Australia</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">3395384</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395384</idno><idno type="RBID">PMC:3395384</idno><idno type="doi">10.1186/1897-4287-10-S2-A11</idno><idno type="pmid">NONE</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">001159</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001159</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers</title><author><name sortKey="Phillips, Ka" sort="Phillips, Ka" uniqKey="Phillips K" first="Ka" last="Phillips">Ka Phillips</name><affiliation><nlm:aff id="I1">Peter MacCallum Cancer Centre, Melbourne, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I2">University of Melbourne, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Milne, Rl" sort="Milne, Rl" uniqKey="Milne R" first="Rl" last="Milne">Rl Milne</name><affiliation><nlm:aff id="I2">University of Melbourne, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Rookus, Ma" sort="Rookus, Ma" uniqKey="Rookus M" first="Ma" last="Rookus">Ma Rookus</name><affiliation><nlm:aff id="I3">Netherlands Cancer Institute, Amsterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Goldgar, D" sort="Goldgar, D" uniqKey="Goldgar D" first="D" last="Goldgar">D. Goldgar</name><affiliation><nlm:aff id="I4">University of Utah, Salt Lake City, USA</nlm:aff></affiliation></author><author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M" last="Friedlander">M. Friedlander</name><affiliation><nlm:aff id="I5">Prince of Wales Hospital, Randwick, Australia</nlm:aff></affiliation></author><author><name sortKey="Mclachlan, Sa" sort="Mclachlan, Sa" uniqKey="Mclachlan S" first="Sa" last="Mclachlan">Sa Mclachlan</name><affiliation><nlm:aff id="I6">St Vincent’s Hospital, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Buys, S" sort="Buys, S" uniqKey="Buys S" first="S" last="Buys">S. Buys</name><affiliation><nlm:aff id="I7">Huntsman Cancer Institute, Salt Lake City, USA</nlm:aff></affiliation></author><author><name sortKey="Antoniou, Ac" sort="Antoniou, Ac" uniqKey="Antoniou A" first="Ac" last="Antoniou">Ac Antoniou</name><affiliation><nlm:aff id="I8">University of Cambridge, Cambridge, UK</nlm:aff></affiliation></author><author><name sortKey="Birch, K" sort="Birch, K" uniqKey="Birch K" first="K" last="Birch">K. Birch</name><affiliation><nlm:aff id="I1">Peter MacCallum Cancer Centre, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Terry, Mb" sort="Terry, Mb" uniqKey="Terry M" first="Mb" last="Terry">Mb Terry</name><affiliation><nlm:aff id="I9">Columbia University, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Easton, Df" sort="Easton, Df" uniqKey="Easton D" first="Df" last="Easton">Df Easton</name><affiliation><nlm:aff id="I8">University of Cambridge, Cambridge, UK</nlm:aff></affiliation></author><author><name sortKey="Weideman, P" sort="Weideman, P" uniqKey="Weideman P" first="P" last="Weideman">P. Weideman</name><affiliation><nlm:aff id="I1">Peter MacCallum Cancer Centre, Melbourne, Australia</nlm:aff></affiliation></author><author><name sortKey="Daly, M" sort="Daly, M" uniqKey="Daly M" first="M" last="Daly">M. Daly</name><affiliation><nlm:aff id="I10">Fox Chase Cancer Center, Philadelphia, USA</nlm:aff></affiliation></author><author><name sortKey="Andrieu, N" sort="Andrieu, N" uniqKey="Andrieu N" first="N" last="Andrieu">N. Andrieu</name><affiliation><nlm:aff id="I11">Institut Curie, Paris, France</nlm:aff></affiliation></author><author><name sortKey="John, Em" sort="John, Em" uniqKey="John E" first="Em" last="John">Em John</name><affiliation><nlm:aff id="I12">Northern California Cancer Center, Fremont, USA</nlm:aff></affiliation></author><author><name sortKey="Hooning, Mj" sort="Hooning, Mj" uniqKey="Hooning M" first="Mj" last="Hooning">Mj Hooning</name><affiliation><nlm:aff id="I13">Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Andrulis, Il" sort="Andrulis, Il" uniqKey="Andrulis I" first="Il" last="Andrulis">Il Andrulis</name><affiliation><nlm:aff id="I14">Ontario Cancer Genetics Network, Cancer Care Ontario, Toronto, Canada</nlm:aff></affiliation></author><author><name sortKey="Caldes, T" sort="Caldes, T" uniqKey="Caldes T" first="T" last="Caldes">T. Caldes</name><affiliation><nlm:aff id="I15">Hospital Clinico San Carlos, Madrid, Spain</nlm:aff></affiliation></author><author><name sortKey="Olsson, H" sort="Olsson, H" uniqKey="Olsson H" first="H" last="Olsson">H. Olsson</name><affiliation><nlm:aff id="I16">Lund University Hospital, Lund, Sweden</nlm:aff></affiliation></author><author><name sortKey="Hopper, Jl" sort="Hopper, Jl" uniqKey="Hopper J" first="Jl" last="Hopper">Jl Hopper</name><affiliation><nlm:aff id="I2">University of Melbourne, Melbourne, Australia</nlm:aff></affiliation></author></analytic><series><title level="j">Hereditary Cancer in Clinical Practice</title><idno type="ISSN">1731-2302</idno><idno type="eISSN">1897-4287</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader></TEI><pmc article-type="abstract" xml:lang="en"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Hered Cancer Clin Pract</journal-id><journal-id journal-id-type="iso-abbrev">Hered Cancer Clin Pract</journal-id><journal-title-group><journal-title>Hereditary Cancer in Clinical Practice</journal-title></journal-title-group><issn pub-type="ppub">1731-2302</issn><issn pub-type="epub">1897-4287</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3395384</article-id><article-id pub-id-type="publisher-id">1897-4287-10-S2-A11</article-id><article-id pub-id-type="doi">10.1186/1897-4287-10-S2-A11</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Phillips</surname><given-names>KA</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Milne</surname><given-names>RL</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Rookus</surname><given-names>MA</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Goldgar</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Friedlander</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>McLachlan</surname><given-names>SA</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Buys</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Antoniou</surname><given-names>AC</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Birch</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Terry</surname><given-names>MB</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Easton</surname><given-names>DF</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Weideman</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Daly</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Andrieu</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>John</surname><given-names>EM</given-names></name><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Hooning</surname><given-names>MJ</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Andrulis</surname><given-names>IL</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Caldes</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I15">15</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Olsson</surname><given-names>H</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Hopper</surname><given-names>JL</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>Peter MacCallum Cancer Centre, Melbourne, Australia</aff><aff id="I2"><label>2</label>University of Melbourne, Melbourne, Australia</aff><aff id="I3"><label>3</label>Netherlands Cancer Institute, Amsterdam, Netherlands</aff><aff id="I4"><label>4</label>University of Utah, Salt Lake City, USA</aff><aff id="I5"><label>5</label>Prince of Wales Hospital, Randwick, Australia</aff><aff id="I6"><label>6</label>St Vincent’s Hospital, Melbourne, Australia</aff><aff id="I7"><label>7</label>Huntsman Cancer Institute, Salt Lake City, USA</aff><aff id="I8"><label>8</label>University of Cambridge, Cambridge, UK</aff><aff id="I9"><label>9</label>Columbia University, New York, USA</aff><aff id="I10"><label>10</label>Fox Chase Cancer Center, Philadelphia, USA</aff><aff id="I11"><label>11</label>Institut Curie, Paris, France</aff><aff id="I12"><label>12</label>Northern California Cancer Center, Fremont, USA</aff><aff id="I13"><label>13</label>Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, Netherlands</aff><aff id="I14"><label>14</label>Ontario Cancer Genetics Network, Cancer Care Ontario, Toronto, Canada</aff><aff id="I15"><label>15</label>Hospital Clinico San Carlos, Madrid, Spain</aff><aff id="I16"><label>16</label>Lund University Hospital, Lund, Sweden</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>12</day><month>4</month><year>2012</year></pub-date><volume>10</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">Familial Aspects of Cancer 2011 Research and Practice</named-content><named-content content-type="supplement-editor">Rodney Scott</named-content></supplement><fpage>A11</fpage><lpage>A11</lpage><permissions><copyright-statement>Copyright ©2012 Phillips et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Phillips et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.hccpjournal.com/content/10/S2/A11"></self-uri><conference><conf-date>23-26 August 2011</conf-date><conf-name>Familial Aspects of Cancer 2011 Research and Practice: A combined meeting of kConFab, Australian Breast Cancer Family Study, Australian Colorectal Cancer Family Study, Australian Ovarian Cancer Study, Family Cancer Clinics of Australia and New Zealand and kConFab</conf-name><conf-loc>Kingscliff, Australia</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>The efficacy of tamoxifen as a breast cancer (BC) prevention strategy for <italic>BRCA1</italic> and <italic>BRCA2</italic> mutation carriers is uncertain.</p></sec><sec sec-type="methods"><title>Patients and methods</title><p>Female <italic>BRCA1</italic> and <italic>BRCA2</italic> mutation carriers, with a personal history of BC since 1970, enrolled in any of the BC family studies, kConFab (Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer), IBCCS (International BRCA1 and BRCA2 Carrier Cohort Study), or BCFR (Breast Cancer Family Registry) were eligible. Those with bilateral disease at first BC diagnosis, tamoxifen use prior to their first BC diagnosis, or another invasive cancer with were excluded. Data were self-reported at entry into the cohort and at follow-up. Hazard ratios (HRs) for development of contralateral BC associated with tamoxifen use after first BC diagnosis were estimated using Cox proportional hazards, modeling time from diagnosis of first primary BC, adjusting for year of birth (continuous), age at diagnosis (continuous), country and bilateral oophorectomy (yes/no, time-varying). Data were censored at contralateral mastectomy, death or loss to follow-up.</p></sec><sec sec-type="results"><title>Results</title><p>Of 1642 <italic>BRCA1</italic> and 919 <italic>BRCA2</italic> mutation carriers, 374 (23%) and 444 (48%), respectively, took tamoxifen after their first BC diagnosis. During 21,344 person-years of follow-up, 596 contralateral BCs were observed. Overall, the adjusted HR estimates were 0.31 (95% CI: 0.22-0.45) and 0.24 (95% CI 0.16-0.35) for <italic>BRCA1</italic> and <italic>BRCA2</italic> mutation carriers, respectively. After left-truncating the analysis at time of recruitment, the adjusted HR estimates were 0.52 (95% CI: 0.26-1.04) and 0.39 (95% CI: 0.17-0.89) from studying 629 <italic>BRCA1</italic> and 412 <italic>BRCA2</italic> mutation carriers, respectively, with 4,869 person-years of follow-up.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Although biased estimates due to non-random use of tamoxifen cannot be excluded, these results are consistent with tamoxifen reducing BC risk for both <italic>BRCA1</italic> and <italic>BRCA2</italic> mutation carriers.</p></sec></body></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001159 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001159 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3395384
|texte= Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:NONE" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |